Abstract
Background
The impact of hypertension control on the risk of end-stage renal disease (ESRD) in patients newly diagnosed with atrial fibrillation (AF) is unknown. This study aimed to investigate the impact of hypertension control on incident ESRD among AF patients.
Methods
From the National Health Information database of Korea, we identified ESRD-free patients who were newly diagnosed with AF during 2010 and 2016. The patients were divided into four groups (NN, NH, HN, and HH) according to combinations of dichotomous blood pressure status [normotensive (N) or hypertensive (H)] of two consecutive check-ups. The primary outcome was incident ESRD. Cox proportional hazard regression analysis evaluated ESRD risks across the groups. The association between ESRD risks and changes in blood pressures was also evaluated.
Results
During the mean follow-up duration of 3.2 ± 1.9 years, 130,259 ESRD-free patients with AF (mean age 63.1 ± 12.1 years, male 61.2%) were evaluated. Compared to NN, other patient groups showed higher ESRD risks [hazard ratio (95% confidence interval) = 1.43 (1.08–1.89), 1.39 (1.08–1.79), and 2.03 (1.55–2.65) for NH, HN, and HH, respectively]. There was a significant trend of decreasing risks of ESRD in patients with greater reductions in systolic blood pressure after AF diagnosis (p for-trend < 0.001). The association between hypertension control and the ESRD risk was more accentuated in patients with chronic kidney disease.
Conclusion
Uncontrolled hypertension was associated with an increased risk of incident ESRD in patients with newly diagnosed AF. This study emphasizes the importance of blood pressure control once patients are diagnosed with AF to prevent ESRD.
Similar content being viewed by others
Availability of data and materials
All raw data are accessible from the designated terminals approved by the National Health Insurance Sharing Service.
Abbreviations
- AF:
-
Atrial fibrillation
- BP:
-
Blood pressure
- CI:
-
Confidence interval
- CKD:
-
Chronic kidney disease
- ESRD:
-
End-stage renal disease
- HR:
-
Hazard ratio
- eGFR:
-
Estimated glomerular filtration rate
- SBP:
-
Systolic blood pressure
References
Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y (2009) Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 158(4):629–636
Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS (2013) Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 127(5):569–574
O’Neal WT, Tanner RM, Efird JT, Baber U, Alonso A, Howard VJ et al (2015) Atrial fibrillation and incident end-stage renal disease: the reasons for geographic and racial differences in stroke (REGARDS) study. Int J Cardiol 185:219–223
Olesen JB, Lip GYH, Kamper AL, Hommel K, Kober L, Lane DA et al (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367(7):625–635
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130(23):e199-267
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al (2020) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42(5):373–498
Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P et al (2009) The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 11(4):423–434
Cha RH, Lee H, Lee JP, Kim YS, Kim SG (2020) The influence of blood pressure patterns on renal outcomes in patients with chronic kidney disease: the long-term follow up result of the APrODiTe-2 study. Medicine. https://doi.org/10.1097/MD.0000000000019209
Choi EK (2020) Cardiovascular research Using the Korean national health information database. Korean Circ J 50(9):754–772
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5):507–520
Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH (2018) Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety. J Am Coll Cardiol 72(8):838–853
Lee SR, Choi EK, Park CS, Han KD, Jung JH, Oh S et al (2019) Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight. J Am Coll Cardiol 73(8):919–931
Lip GYH (2017) The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 14(11):627–628
Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY et al (2018) Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol 72(11):1233–1245
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JRJC et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64(21):e1-76
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D et al (2020) 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 75(6):1334–1357
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Himmelfarb CD et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71(6):e13–e115
Funding
This study was supported by grant no 3020200190 from the Seoul National University Hospital Research Fund, by the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, Republic of Korea, the Ministry of Food and Drug Safety) (Project Number: 202013B14), and by the Korea National Research Foundation funded by the Ministry of Education, Science and Technology (grant 2020R1F1A106740).
Author information
Authors and Affiliations
Contributions
Conceptualization: SK, SRL, EKC, JHJ, KDH, GYHL, and OS, data curation: SK, SRL, EKC, JHJ, KDH, GYHL, and OS, formal analysis: SK, SRL, EKC, JHJ, KDH, GYHL, and OS, funding acquisition: EKC, investigation: SK, SRL, EKC, JHJ, and KDH, methodology: SK, SRL, EKC, JHJ, KDH, GYHL, and OS, project administration: EKC, and KDH, resources: SRL, EKC, and KDH, software: SK, SRL, JHJ, and KDH, supervision: SRL, EKC, KDH, GYHL, and OS, validation: SK, SRL, EKC, JHJ, and KDH, visualization: SK and JHJ, writing—original draft: SK and SRL, figure and table generation: SK and SRL, writing—review and editing: SK, SRL, EKC, JHJ, KDH, GYHL and OS. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
SK, SRL, JHJ, KDH, SO: none to disclose. EKC: research grants from Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daiichi-Sankyo, Samjinpharm, Sanofi-Aventis, Seers Technology, Skylabs, and Yuhan. No fees are received personally. GYHL: consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are received personally.
Ethical approval consent to participate
The Institutional Review Board of Seoul National University Hospital approved the study (No. 2008–048-1147) and adhered to the Declaration of Helsinki. Informed consent was exempted because the study used anonymous data.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kwon, S., Lee, SR., Choi, EK. et al. Hypertension control and end-stage renal disease in atrial fibrillation: a nationwide population-based cohort study. Clin Res Cardiol 111, 284–293 (2022). https://doi.org/10.1007/s00392-021-01899-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-021-01899-8